Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T. Sunami K, et al. Among authors: kubo t. JAMA Oncol. 2024 Jan 1;10(1):95-102. doi: 10.1001/jamaoncol.2023.5120. JAMA Oncol. 2024. PMID: 38032680 Free PMC article.
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.
Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, Teramoto N, Yamashita M, Toyooka S, Tanimoto M, Kiura K. Takata S, et al. Among authors: kubo t. Lung Cancer. 2012 Jan;75(1):24-9. doi: 10.1016/j.lungcan.2011.05.015. Lung Cancer. 2012. PMID: 21684622
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Ichihara E, Kuyama S, Kudo K, Bessho A, Sakugawa M, Fujimoto N, Aoe K, Minami D, Sugimoto K, Ochi N, Takigawa N, Hotta K, Maeda Y, Kiura K. Ninomiya T, et al. Among authors: kubo t. Jpn J Clin Oncol. 2021 Aug 1;51(8):1269-1276. doi: 10.1093/jjco/hyab084. Jpn J Clin Oncol. 2021. PMID: 34115855 Clinical Trial.
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K, Ichikawa H, Kato Y, Oda N, Oze I, Tamura T, Kozuki T, Umeno T, Kubo T, Hotta K, Bessho A, Maeda Y, Kiura K. Hosokawa S, et al. Among authors: kubo t. Int J Clin Oncol. 2022 Jul;27(7):1139-1144. doi: 10.1007/s10147-022-02164-2. Epub 2022 May 10. Int J Clin Oncol. 2022. PMID: 35534642 Clinical Trial.
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K. Aoe K, et al. Among authors: kubo t. Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26. Eur J Cancer. 2014. PMID: 25172295 Clinical Trial.
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Ichihara E, et al. Among authors: kubo t. J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434. J Thorac Oncol. 2015. PMID: 25695221 Free article. Clinical Trial.
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K. Kubo T, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):769-74. doi: 10.1007/s00280-016-3135-2. Epub 2016 Aug 20. Cancer Chemother Pharmacol. 2016. PMID: 27544764 Clinical Trial.
4,309 results